Compare GHI & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Current Price
| Metric | GHI | TKNO |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.1M | 236.6M |
| IPO Year | N/A | 2021 |
| Metric | GHI | TKNO |
|---|---|---|
| Price | $6.46 | $4.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 155.1K | 136.3K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 22.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | $26,247,399.00 | ★ $39,801,000.00 |
| Revenue This Year | $201.02 | $8.79 |
| Revenue Next Year | $2.87 | $10.52 |
| P/E Ratio | $38.77 | ★ N/A |
| Revenue Growth | N/A | ★ 9.50 |
| 52 Week Low | $6.01 | $3.94 |
| 52 Week High | $13.29 | $10.37 |
| Indicator | GHI | TKNO |
|---|---|---|
| Relative Strength Index (RSI) | 34.79 | 46.51 |
| Support Level | $6.46 | $4.50 |
| Resistance Level | $6.73 | $4.94 |
| Average True Range (ATR) | 0.28 | 0.24 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 18.50 | 37.74 |
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.